Cargando…
National Incidence, Management and Survival of Urachal Carcinoma
Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were iden...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064294/ https://www.ncbi.nlm.nih.gov/pubmed/27746878 http://dx.doi.org/10.4081/rt.2016.6257 |
_version_ | 1782460128453197824 |
---|---|
author | Collins, Dearbhaile C. Velázquez-Kennedy, Kyra Deady, Sandra Brady, Adrian P. Sweeney, Paul Power, Derek G. |
author_facet | Collins, Dearbhaile C. Velázquez-Kennedy, Kyra Deady, Sandra Brady, Adrian P. Sweeney, Paul Power, Derek G. |
author_sort | Collins, Dearbhaile C. |
collection | PubMed |
description | Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5 vs. 1.9 yrs), patients under 50 years of age (3.6 vs. 1.9 yrs), those without confirmed metastasis (4.1 vs. 0.7 yrs) and those who received chemotherapy (3.6 vs. 2.6 yrs). The overall survival of urachal carcinoma in Ireland is less than expected from published literature. This study highlights the need for centralization of rare tumors with international collaboration to identify the optimal treatment strategy and improve outcome. |
format | Online Article Text |
id | pubmed-5064294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | PAGEPress Publications, Pavia, Italy |
record_format | MEDLINE/PubMed |
spelling | pubmed-50642942016-10-14 National Incidence, Management and Survival of Urachal Carcinoma Collins, Dearbhaile C. Velázquez-Kennedy, Kyra Deady, Sandra Brady, Adrian P. Sweeney, Paul Power, Derek G. Rare Tumors Article Urachal carcinoma is an uncommon cancer whose rarity has precluded its study and evidence-based management strategies are lacking. This study assessed all urachal carcinomas in Ireland and clinical parameters in order to improve understanding. Urachal carcinomas diagnosed from 1994 to 2011 were identified from the National Cancer Registry in Ireland. Data obtained included patient age, gender, diagnostic year, pathology, tumor stage, patient treatment strategies and survival. Twenty-six urachal carcinomas were identified, the majority being adenocarcinoma. This comprised 0.3% of all invasive bladder tumors. Patients were predominantly male (62%) and over 50 years of age (58%). Twenty-two patients (85%) underwent surgery, with only six (23%) undergoing chemotherapy. On average, median overall survival was 2.6 years (range 0-15.2 yrs). Survival was longer in women (5 vs. 1.9 yrs), patients under 50 years of age (3.6 vs. 1.9 yrs), those without confirmed metastasis (4.1 vs. 0.7 yrs) and those who received chemotherapy (3.6 vs. 2.6 yrs). The overall survival of urachal carcinoma in Ireland is less than expected from published literature. This study highlights the need for centralization of rare tumors with international collaboration to identify the optimal treatment strategy and improve outcome. PAGEPress Publications, Pavia, Italy 2016-10-05 /pmc/articles/PMC5064294/ /pubmed/27746878 http://dx.doi.org/10.4081/rt.2016.6257 Text en ©Copyright D.C. Collins et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Collins, Dearbhaile C. Velázquez-Kennedy, Kyra Deady, Sandra Brady, Adrian P. Sweeney, Paul Power, Derek G. National Incidence, Management and Survival of Urachal Carcinoma |
title | National Incidence, Management and Survival of Urachal Carcinoma |
title_full | National Incidence, Management and Survival of Urachal Carcinoma |
title_fullStr | National Incidence, Management and Survival of Urachal Carcinoma |
title_full_unstemmed | National Incidence, Management and Survival of Urachal Carcinoma |
title_short | National Incidence, Management and Survival of Urachal Carcinoma |
title_sort | national incidence, management and survival of urachal carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064294/ https://www.ncbi.nlm.nih.gov/pubmed/27746878 http://dx.doi.org/10.4081/rt.2016.6257 |
work_keys_str_mv | AT collinsdearbhailec nationalincidencemanagementandsurvivalofurachalcarcinoma AT velazquezkennedykyra nationalincidencemanagementandsurvivalofurachalcarcinoma AT deadysandra nationalincidencemanagementandsurvivalofurachalcarcinoma AT bradyadrianp nationalincidencemanagementandsurvivalofurachalcarcinoma AT sweeneypaul nationalincidencemanagementandsurvivalofurachalcarcinoma AT powerderekg nationalincidencemanagementandsurvivalofurachalcarcinoma |